NCT01900704

Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 810 (actual)
• Sponsor: Serenity Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 50 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia

Conditions

• Nocturia

Interventions

Type	Name	Description
DRUG	SER120 750 ng	SER120 750 ng
DRUG	SER120 1500 ng	SER120 1500 ng
DRUG	Placebo	Placebo

Timeline

• Start date: 2013-08-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2013-07-16
• Last updated: 2020-11-09
• Results posted: 2020-11-09

Locations

1 site across 1 country: United States